Search results
13 paź 2022 · The primary treatment for UCS is surgical debulking, followed by adjuvant therapy including both chemotherapy and radiotherapy [10]. Even after receiving such aggressive treatment, high recurrence rates were encountered in 37%, 46%, 63%, and 80% of stages I, II, III, and IV patients, respectively [1].
23 maj 2022 · The overall five-year relative survival rate for uterine cancer is 81 percent, according to the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database. More specifically, the five-year survival rates are broken down between localized, regional and distant uterine cancer, as listed below.
Overall survival was 52%, relapse-free - 32%, for stage I – II it reached 72.2%. Five-year survival for stage III was 44.4%. Recurrence rate after total hysterectomy with pelvic lymphadenectomy was 2 times lower compared to that without lymphadenectomy (30 and 62.5%, respectively).
9 sty 2023 · Adding adjuvant radiotherapy to adjuvant chemotherapy after radical surgery may significantly reduce risk of local and overall recurrence, while significantly improving survival of patients with stage III endometrial cancer.
10 cze 2021 · Uncertainties remain about the most effective treatment for uterine carcinosarcoma, a rare but aggressive form of uterine cancer. This study used clinical data from several treatment centers to investigate whether removing lymph nodes or giving adjuvant therapies after hysterectomy offered any survival benefit.
14 gru 2021 · In the last decade, the improved selection of patients with recurrent endometrial cancer resulted in an improved 5-year survival rate from 25% up to 75%. The treatment modalities can be either local (surgery and radiotherapy) or systemic (chemotherapy, targeted therapy, hormonal therapy, or immunotherapy).
17 maj 2012 · Leiomyosarcoma, the most frequent pure uterine sarcoma, is an aggressive tumor with a tendency toward early relapse. Survival for patients with recurrent disease is poor. In contrast, endometrial stromal sarcoma, the second most common uterine sarcoma, is a more indolent malignancy with a tendency toward recurrence after a long latency period.
